NICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib) in untreated kidney cancer, citing uncertainties about its lon
Sanofi’s Dupixent (dupilumab) has been cleared for NHS funding in Wales and Scotland in adolescents with severe eczema, also known as atopic dermatitis.
